COEP Insider Trading
Insider Ownership Percentage: 24.25%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Coeptis Therapeutics Share Price & Price History
Current Price: $9.27
Price Change: ▼ Price Decrease of -0.29 (-3.03%)
As of 01/17/2025 05:00 PM ET
Coeptis Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/12/2024 | Tara Desilva | Director | Buy | 113 | $11.60 | $1,310.80 | 1,613 |  |
| 1/10/2024 | Brian Cogley | CFO | Buy | 250 | $13.40 | $3,350.00 | 1,500 | |
| 1/8/2024 | David Mehalick | CEO | Buy | 1,000 | $13.20 | $13,200.00 | 139,130 | |
| 1/5/2024 | Daniel Alexander Yerace | VP | Buy | 542 | $13.80 | $7,479.60 | 53,572 | |
| 1/5/2024 | David Mehalick | CEO | Buy | 252 | $13.80 | $3,477.60 | 138,130 | |
| 1/5/2024 | Gene Salkind | Director | Buy | 580 | $13.80 | $8,004.00 | 14,202 | |
| 8/29/2023 | Gene Salkind | Director | Buy | 200 | $20.20 | $4,040.00 | 202 | |
| 8/25/2023 | Gene Salkind | Director | Buy | 1,431 | $18.20 | $26,044.20 | 1,431 | |
| 8/23/2023 | Chris Calise | Director | Buy | 579 | $18.80 | $10,885.20 | 73,244 | |
Coeptis Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/13/2024 | Armistice Capital LLC | 3,520,000 | $2.76M | 0.0% | +59.1% | 10.320% |  |
| 11/15/2023 | Armistice Capital LLC | 2,212,000 | $2.57M | 0.0% | -5.1% | 8.799% | |
| 8/15/2023 | Ionic Capital Management LLC | 45,000 | $70K | 0.0% | N/A | 0.209% | |
| 7/21/2023 | Creative Planning | 645,103 | $1M | 0.0% | N/A | 2.995% | |
| 5/12/2023 | Antara Capital LP | 45,000 | $64K | 0.0% | N/A | 0.220% | |
| 2/14/2023 | Susquehanna International Group LLP | 16,341 | $25K | 0.0% | N/A | 0.319% | |
| 2/10/2023 | Creative Planning | 645,103 | $0.99M | 0.0% | N/A | 12.600% | |
| 2/10/2023 | HRT Financial LP | 172,635 | $0.27M | 0.0% | N/A | 3.372% | |
| 2/8/2023 | Cambridge Investment Research Advisors Inc. | 31,670 | $48K | 0.0% | N/A | 0.619% | |
| 2/6/2023 | West Chester Capital Advisors Inc. | 2,863,382 | $4.39M | 8.7% | N/A | 55.925% | |
Data available starting January 2016
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Read More on Coeptis Therapeutics
Volume
44,723 shs
Average Volume
353,229 shs
Market Capitalization
$19.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Coeptis Therapeutics?
